SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/30/22 Baxter International Inc. 8-K:1,7,9 9/28/22 17:10M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 43K 2: EX-10.1 Material Contract HTML 78K 3: EX-10.2 Material Contract HTML 694K 4: EX-10.3 Material Contract HTML 48K 5: EX-10.4 Material Contract HTML 704K 6: EX-10.5 Material Contract HTML 677K 7: EX-99.1 Miscellaneous Exhibit HTML 32K 12: R1 Document and Entity Information HTML 58K 15: XML IDEA XML File -- Filing Summary XML 15K 13: XML XBRL Instance -- d378856d8k_htm XML 26K 14: EXCEL IDEA Workbook of Financial Reports XLSX 8K 9: EX-101.DEF XBRL Definitions -- bax-20220928_def XML 44K 10: EX-101.LAB XBRL Labels -- bax-20220928_lab XML 72K 11: EX-101.PRE XBRL Presentations -- bax-20220928_pre XML 46K 8: EX-101.SCH XBRL Schema -- bax-20220928 XSD 18K 16: JSON XBRL Instance as JSON Data -- MetaLinks 15± 23K 17: ZIP XBRL Zipped Folder -- 0001193125-22-255523-xbrl Zip 525K
8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i September 28, 2022
Baxter International Inc.
(Exact name of registrant as specified in its charter)
i Delaware | i 1-4448 | i 36-0781620 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
i One Baxter Parkway, i Deerfield, i Illinois | i 60015 | |
(Address of principal executive offices) | (Zip Code) |
i (224) i 948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b)) |
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
i Common Stock, $1.00 par value | i BAX (NYSE) | i New York Stock Exchange | ||
i Chicago Stock Exchange | ||||
i 0.4% Global Notes due 2024 | i BAX 24 | i New York Stock Exchange | ||
i 1.3% Global Notes due 2025 | i BAX 25 | i New York Stock Exchange | ||
i 1.3% Global Notes due 2029 | i BAX 29 | i New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
i ☐ Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 1.01 | Entry into a Material Definitive Agreement |
Credit Agreements
U.S. $4,000,000,000 Term Loan Credit Agreement
On September 28, 2022, Baxter International Inc. (“Baxter”) entered into a first amendment (the “Term Loan First Amendment”) to the existing $4.0 billion term loan credit facility, dated as of September 30, 2021 (as amended by the Term Loan First Amendment, the “First Amended Term Loan Credit Agreement”), among Baxter, as Borrower, various lenders and JPMorgan Chase Bank, National Association, as Administrative Agent. The purpose of the Term Loan First Amendment was to amend the net leverage ratio covenant to extend the net leverage ratio step-down schedule by four fiscal quarters, beginning with the first scheduled step down which had been scheduled to occur with respect to the quarter ending March 31, 2023.
On September 28, 2022, Baxter entered into a second amendment (the “Term Loan Second Amendment” and together with the Term Loan First Amendment, the “Term Loan Amendments”) to the First Amended Term Loan Credit Agreement (as amended by the Term Loan Second Amendment, the “Term Loan Credit Agreement”), among Baxter, as Borrower, various lenders and JPMorgan Chase Bank, National Association, as Administrative Agent. The purpose of the Term Loan Second Amendment was to transition the benchmark rate from LIBOR to Term SOFR.
The description above is a summary of the Term Loan Amendments and is qualified in its entirety by the complete texts of the Term Loan Amendments, copies of which are attached to this report as Exhibits 10.1 and 10.2 and incorporated herein by reference. Capitalized terms used under this “U.S. $4,000,000,000 Term Loan Credit Agreement” subsection that are not defined herein have the meanings given to them in the Term Loan Amendments, as applicable.
U.S. $2,500,000,000 Five-Year Credit Agreement
On September 28, 2022, Baxter entered into a first amendment (the “USD Revolving First Amendment”) to the existing $2.5 billion, five-year revolving credit agreement, dated as of September 30, 2021 (as amended by the USD Revolving First Amendment, the “First Amended USD Revolving Credit Agreement”), among Baxter, as Borrower, various lenders and JPMorgan Chase Bank, National Association, as Administrative Agent. The purpose of the USD Revolving First Amendment was to amend the net leverage ratio covenant to extend the net leverage ratio step-down schedule by four fiscal quarters, beginning with the first scheduled step down which had been scheduled to occur with respect to the quarter ending March 31, 2023.
On September 28, 2022, Baxter entered into a second amendment (the “USD Revolving Second Amendment” and together with the USD Revolving First Amendment, the “USD Revolving Amendments”) to the First Amended USD Revolving Credit Agreement (as amended by the USD Revolving Second Amendment, the “USD Revolving Credit Agreement”), among Baxter, as Borrower, various lenders and JPMorgan Chase Bank, National Association, as Administrative Agent. The purpose of the USD Revolving Second Amendment was to transition the benchmark rate from LIBOR to Term SOFR.
The description above is a summary of the USD Revolving Amendments and is qualified in its entirety by the complete texts of the USD Revolving Amendments, copies of which are attached to this report as Exhibits 10.3 and 10.4 and incorporated herein by reference. Capitalized terms used under this “U.S. $2,500,000,000 Five-Year Credit Agreement” subsection that are not defined herein have the meanings given to them in the USD Revolving Amendments, as applicable.
Amendment to Existing €200,000,000 Credit Agreement
On September 28, 2022, Baxter Healthcare SA and Baxter World Trade SRL (the “Euro Borrowers”) and their existing lender group entered into a second amendment (the “Euro Amendment”) to the existing €200 million revolving credit facility, dated as of December 20, 2019, as amended by that certain First Amendment, dated as of October 1, 2021 (the “Existing Euro Revolving Credit Agreement” and, as amended by the Euro Amendment, the “Euro Revolving Credit Agreement”), among the Euro Borrowers, as Borrowers, various lenders, and J.P. Morgan SE, as Administrative Agent, and the related Guaranty by Baxter, as Guarantor. The purpose of the Euro Amendment was to amend the net leverage ratio covenant in the Guaranty to extend the net leverage ratio step-down schedule by four fiscal quarters, beginning with the first scheduled step down which had been scheduled to occur with respect to the quarter ending March 31, 2023.
The description above is a summary of the Euro Amendment and is qualified in its entirety by the complete text of the Euro Amendment, a copy of which is attached to this report as Exhibit 10.5 and incorporated herein by reference. Capitalized terms used under this “Amendment to Existing €200,000,000 Credit Agreement” subsection that are not defined herein have the meanings given to them in the Euro Amendment.
Item 7.01 | Regulation FD Disclosure. |
The presentation furnished herewith as Exhibit 99.1 is being provided to certain stockholders on or after October 3, 2022, as part of Baxter International Inc.’s annual stockholder engagement program.
The information in Section 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 30, 2022
BAXTER INTERNATIONAL INC. | ||
By: | ||
Ellen K. Bradford | ||
Senior Vice President and Corporate Secretary |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
3/31/23 | ||||
10/3/22 | ||||
Filed on: | 9/30/22 | |||
For Period end: | 9/28/22 | |||
10/1/21 | ||||
9/30/21 | 10-Q, 8-K | |||
12/20/19 | 8-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/08/24 Baxter International Inc. 10-K 12/31/23 173:23M Workiva Inc Wde… FA01/FA 2/09/23 Baxter International Inc. 10-K 12/31/22 163:22M Workiva Inc Wde… FA01/FA 10/27/22 Baxter International Inc. 10-Q 9/30/22 93:10M Workiva Inc Wde… FA01/FA |